Technical Analysis for APRE - Aprea Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| 50 DMA Resistance | Bearish | -5.72% | |
| Stochastic Sell Signal | Bearish | -5.72% | |
| 20 DMA Support | Bullish | -5.72% | |
| Weak + Overbought | Other | -5.72% | |
| Outside Day | Range Expansion | -5.72% | |
| Overbought Stochastic | Strength | -5.72% | |
| Upper Bollinger Band Touch | Strength | -5.72% |
| Alert | Time |
|---|---|
| 10 DMA Support | 2 days ago |
| Down 3% | 2 days ago |
| Up 3% | 2 days ago |
| Down 2 % | 2 days ago |
| Down 1% | 2 days ago |
Get this analysis on your stocks daily!
- Earnings date: 05/13/2024
Aprea Therapeutics, Inc. Description
Aprea Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. The company's lead drug candidate APR-246, a small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as additional hematologic and solid tumor malignancies. It has commenced a Phase 3 clinical trial in p53 mutant MDS and completed enrollment in a Phase 1b/2 clinical trial in p53 mutant MDS and AML with APR-246 and azacitidine; and additional Phase 1/2 trials of APR-246 in MDS and AML in combination with approved anti-cancer therapies, as well as developing next generation p53 reactivators. The company was founded in 2003 and is based in Boston, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Development Tumor Acute Myeloid Leukemia Cancer Therapies Myelodysplastic Syndrome Syndromes P53 Tumor Suppressor Genes Anti Cancer Therapies Tumor Suppressor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.8465 |
| 52 Week Low | 2.78 |
| Average Volume | 34,988 |
| 200-Day Moving Average | 4.97 |
| 50-Day Moving Average | 5.84 |
| 20-Day Moving Average | 5.36 |
| 10-Day Moving Average | 5.48 |
| Average True Range | 0.39 |
| RSI (14) | 43.50 |
| ADX | 21.19 |
| +DI | 15.11 |
| -DI | 17.59 |
| Chandelier Exit (Long, 3 ATRs) | 4.74 |
| Chandelier Exit (Short, 3 ATRs) | 6.06 |
| Upper Bollinger Bands | 5.82 |
| Lower Bollinger Band | 4.91 |
| Percent B (%b) | 0.4 |
| BandWidth | 17.02 |
| MACD Line | -0.07 |
| MACD Signal Line | -0.13 |
| MACD Histogram | 0.0604 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.07 | ||||
| Resistance 3 (R3) | 6.15 | 5.98 | 5.93 | ||
| Resistance 2 (R2) | 5.98 | 5.77 | 5.93 | 5.89 | |
| Resistance 1 (R1) | 5.62 | 5.65 | 5.54 | 5.54 | 5.84 |
| Pivot Point | 5.45 | 5.45 | 5.40 | 5.40 | 5.45 |
| Support 1 (S1) | 5.09 | 5.24 | 5.01 | 5.01 | 4.70 |
| Support 2 (S2) | 4.92 | 5.12 | 4.87 | 4.65 | |
| Support 3 (S3) | 4.56 | 4.92 | 4.61 | ||
| Support 4 (S4) | 4.48 |
